Acadia Pharmaceuticals Inc’s recent filing unveils that its Director Brege Laura unloaded Company’s shares for reported $0.31 million on Jun 04 ’25. In the deal valued at $21.78 per share,14,446 shares were sold. As a result of this transaction, Brege Laura now holds 15,095 shares worth roughly $0.33 million.
Then, LAURA BREGE bought 14,446 shares, generating $314,638 in total proceeds.
Before that, Kihara James sold 4,000 shares. Acadia Pharmaceuticals Inc shares valued at $90,000 were divested by the PRINCIPAL ACCOUNTING OFFICER at a price of $22.50 per share. As a result of the transaction, Kihara James now holds 20,395 shares, worth roughly $0.45 million.
Deutsche Bank upgraded its Acadia Pharmaceuticals Inc [ACAD] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid February with a ‘”a Hold”‘ rating. Guggenheim also remained covering ACAD and has decreased its forecast on January 03, 2025 with a “Neutral” recommendation from previously “Buy” rating.
Price Performance Review of ACAD
On Monday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock jump 1.98% to $22.14. Over the last five days, the stock has lost -0.72%. Acadia Pharmaceuticals Inc shares have risen nearly 20.65% since the year began. Nevertheless, the stocks have risen 44.05% over the past one year. While a 52-week high of $25.23 was reached on 05/16/25, a 52-week low of $13.40 was recorded on 04/09/25.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 21.61, which if violated will result in even more drops to 21.07. On the upside, there is a resistance level at 22.42. A further resistance level may holdings at 22.69.
